Journal
PHARMACOGENOMICS JOURNAL
Volume 16, Issue 2, Pages 141-146Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2015.30
Keywords
-
Categories
Funding
- Research Council at Herlev Hospital
- Danish Rheumatism Association
- Danish Medical Association Research Foundation
- Aase og Ejnar Danielsens Fond
- Fonden til Laegevidenskabens Fremme
- Scandinavian Journal of Rheumatology
- Dagmar Marshalls Fond
- Bevica Foundation
- Direktor Jacob Madsen og Hustru Olga Madsens Fond
- Torben og Alice Frimodts Fond
- Axel Muusfeldt fond
- Abbvie/Abbott Laboratories, Denmark
- Meda Pharmaceuticals, Denmark
Ask authors/readers for more resources
At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents, which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naive RA patients enrolled in the OPtimized treatment algorithm for patients with early RA (OPERA) Study, an investigator-initiated, prospective, double-blind placebo-controlled study. Patients were randomized to adalimumab 40 mg (n = 89) or placebo-adalimumab (n = 91) subcutaneously in combination with methotrexate. Expressions of 377 miRNAs were determined using TaqMan Human MicroRNA LDA, A Card v2.0 (Applied Biosystems). Associations between miRNAs and treatment response were tested using interaction analyses. MiRNAs with a P-value <0.05 using three different normalizations were included in a multivariate model. After backwards elimination, the combination of low expression of miR-22 and high expression of miR-886.3p was associated with EULAR good response. Future studies to assess the utility of these miRNAs as predictive biomarkers are needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available